According to an article published by Veterinary Practice News in June 2020, the prevalence of osteoarthritis in dogs was found to be 20% globally. Similarly, according to an article published by American Animal Health Association in April 2021, approximately 6 million dogs are diagnosed with cancer each year.
There is a growing awareness among pet owners about animal welfare, which has led to an increased demand for pain management products and services to ensure that their pets are comfortable and pain-free. Many pet owners are not aware of the importance of pain management for their pets. This lack of awareness can lead to underdiagnosis and undertreatment of pain in pets, which can negatively impact the growth of the market. The cost of veterinary pain management products and services can be relatively high, which can limit their accessibility to pet owners, particularly in developing countries. Some pain management drugs may have side effects that can be harmful to pets. This can lead to safety concerns among pet owners, which can negatively impact the growth of the market. There is a shortage of pain management specialists in the veterinary field, which can limit the availability of specialized pain management services. The development and approval of pain management products for veterinary use are subject to stringent regulatory requirements, which can be time-consuming and costly. Alternative therapies, such as acupuncture and herbal remedies, are becoming increasingly popular among pet owners as an alternative to traditional pain management products and services. This can impact the growth of the market. The advantages of veterinary pain management are numerous, and they are essential for maintaining the health and well-being of our animal companions.
Growing Prevalence of Chronic Diseases
Seventy percent of U.S. households, or about 90.5 million families, own a pet, according to the 2021-2022 National Pet Owners Survey conducted by the American Pet Products Association (APPA).
Increasing Investment in the Pet Healthcare Sector
The total number of pets insured in the U.S. at 2021 was 3.9 million, a 28 percent increase since 2020.
Recent Development
- In February 2021, Dechra Pharmaceuticals PLC received rights for marketing Tri-Solfen in Australia and New Zealand under a licensing agreement with Animal Ethics Pty Ltd. Tri-Solfen is used as a routine treatment in reducing pain for farm animals.
- In July 2020, Boehringer Ingelheim acquired a Belgian biotech company, GST, to strengthen its stem cell capabilities in the Animal Health segment.
Market Segmentation
Global veterinary pain management market can be segmented by product, by application, by animal type and by region. Based on product, the market can be divided into Medications and Medical Devices. Based on application, the market can be differentiated into Joint Pain, Cancer Pain, Postoperative Pain, Others. Based on application, the market can be divided into Companion Animal and Livestock Animal. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East and Africa and South America. Among the different countries, United States dominated the global veterinary pain management market on account of growing incidence of animal diseases in the country.
Market Players
Boehringer Ingelheim International GmbH, Zoetis Inc., Elanco Animal Health Incorporated, Norbrook Laboratories Limited, SeQuent Scientific Limited, Merck & Co., Inc., Dechra Pharmaceuticals Plc, Vetoquinol S.A., Ceva Santé Animale SA, Chanelle Pharma Group Ltd are some of the leading players operating in the global veterinary pain management market.
Attribute | Details |
Base Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | · By Product · By Application · By Animal Type · By Region |
Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
Country scope | United States; Mexico; Canada; France; Germany; United Kingdom; Italy; Spain; China; India; South Korea; Japan; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE; Egypt; Turkey |
Key companies profiled | Boehringer Ingelheim International GmbH, Zoetis Inc., Elanco Animal Health Incorporated, Norbrook Laboratories Limited, SeQuent Scientific Limited, Merck & Co., Inc., Dechra Pharmaceuticals Plc, Vetoquinol S.A., Ceva Santé Animale SA, Chanelle Pharma Group Ltd |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |